IPO
-
-
-
-
-
-
-
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
-
-
-
-
-
-
-
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
-
-
-
-
-
-
-
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
-
-
-
-
-
-
-
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
-
-
-
-
-
-
-
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
-
-
-
-
-
-
-
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
-
-
-
-
-
-
-
CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study
-
99,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All